These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 12172093)

  • 1. M184V is associated with a low incidence of thymidine analogue mutations and low phenotypic resistance to zidovudine and stavudine.
    Ait-Khaled M; Stone C; Amphlett G; Clotet B; Staszewski S; Katlama C; Tisdale M;
    AIDS; 2002 Aug; 16(12):1686-9. PubMed ID: 12172093
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thymidine analog and multinucleoside resistance mutations are associated with decreased phenotypic susceptibility to stavudine in HIV type 1 isolated from zidovudine-naive patients experiencing viremia on stavudine-containing regimens.
    Ross L; Scarsella A; Raffanti S; Henry K; Becker S; Fisher R; Liao Q; Hirani A; Graham N; St Clair M; Hernandez J;
    AIDS Res Hum Retroviruses; 2001 Aug; 17(12):1107-15. PubMed ID: 11522180
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diminished selection for thymidine-analog mutations associated with the presence of M184V in Ethiopian children infected with HIV subtype C receiving lamivudine-containing therapy.
    Averbuch D; Schapiro JM; Lanier ER; Gradstein S; Gottesman G; Kedem E; Einhorn M; Grisaru-Soen G; Ofir M; Engelhard D; Grossman Z
    Pediatr Infect Dis J; 2006 Nov; 25(11):1049-56. PubMed ID: 17072129
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phenotypic and genotypic resistance to nucleoside reverse transcriptase inhibitors in HIV-1 clinical isolates.
    Lafeuillade A; Poggi C; Hittinger G; Chadapaud S
    HIV Med; 2001 Oct; 2(4):231-5. PubMed ID: 11737402
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of genotypic and phenotypic resistance patterns of human immunodeficiency virus type 1 isolates from patients treated with stavudine and didanosine or zidovudine and lamivudine.
    Picard V; Angelini E; Maillard A; Race E; Clavel F; Chêne G; Ferchal F; Molina JM
    J Infect Dis; 2001 Sep; 184(6):781-4. PubMed ID: 11517441
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phenotypic resistance pattern of HIV-1 isolates with zidovudine and/or multidrug resistance mutations after didanosine-stavudine combination therapy.
    Pellegrin I; Segondy M; Garrigue I; Izopet J; Montes B; Pellegrin JL; Reynes J; Massip P; Puel J; Fleury H
    J Acquir Immune Defic Syndr; 2000 Dec; 25(5):465-6. PubMed ID: 11141248
    [No Abstract]   [Full Text] [Related]  

  • 7. Thymidine analogue reverse transcriptase inhibitors resistance mutations profiles and association to other nucleoside reverse transcriptase inhibitors resistance mutations observed in the context of virological failure.
    Marcelin AG; Delaugerre C; Wirden M; Viegas P; Simon A; Katlama C; Calvez V
    J Med Virol; 2004 Jan; 72(1):162-5. PubMed ID: 14635026
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evidence of stavudine-related phenotypic resistance among zidovudine-pretreated HIV-1-infected subjects receiving a therapeutic regimen of stavudine plus lamivudine.
    Milazzo L; Rusconi S; Testa L; La Seta-Catamancio S; Galazzi M; Kurtagic S; Citterio P; Gianotto M; Grassini A; Adorni F; d'Arminio-Monforte A; Galli M; Moroni M
    J Acquir Immune Defic Syndr; 1999 Sep; 22(1):101-3. PubMed ID: 10534153
    [No Abstract]   [Full Text] [Related]  

  • 9. Subtle decreases in stavudine phenotypic susceptibility predict poor virologic response to stavudine monotherapy in zidovudine-experienced patients.
    Shulman NS; Hughes MD; Winters MA; Shafer RW; Zolopa AR; Hellmann NS; Bates M; Whitcomb JM; Katzenstein DA
    J Acquir Immune Defic Syndr; 2002 Oct; 31(2):121-7. PubMed ID: 12394789
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The M184V mutation in HIV-1 reverse transcriptase (RT) conferring lamivudine resistance does not result in broad cross-resistance to nucleoside analogue RT inhibitors.
    Miller V; Stürmer M; Staszewski S; Gröschel B; Hertogs K; de Béthune MP; Pauwels R; Harrigan PR; Bloor S; Kemp SD; Larder BA
    AIDS; 1998 May; 12(7):705-12. PubMed ID: 9619801
    [TBL] [Abstract][Full Text] [Related]  

  • 11. N348I in the connection domain of HIV-1 reverse transcriptase confers zidovudine and nevirapine resistance.
    Yap SH; Sheen CW; Fahey J; Zanin M; Tyssen D; Lima VD; Wynhoven B; Kuiper M; Sluis-Cremer N; Harrigan PR; Tachedjian G
    PLoS Med; 2007 Dec; 4(12):e335. PubMed ID: 18052601
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term foscarnet therapy remodels thymidine analogue mutations and alters resistance to zidovudine and lamivudine in HIV-1.
    Mathiesen S; Dam E; Roge B; Joergensen LB; Laursen AL; Gerstoft J; Clavel F
    Antivir Ther; 2007; 12(3):335-43. PubMed ID: 17591023
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thymidine-analog and multi-nucleoside resistance mutations are observed in both zidovudine-naive and zidovudine-experienced subjects with viremia after treatment with stavudine-containing regimens.
    Ross L; Henry K; Paar D; Salvato P; Shaefer M; Fisher R; Liao Q; St Clair M
    J Hum Virol; 2001; 4(4):217-22. PubMed ID: 11694850
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HIV-1 reverse transcriptase (RT) genotype and susceptibility to RT inhibitors during abacavir monotherapy and combination therapy.
    Miller V; Ait-Khaled M; Stone C; Griffin P; Mesogiti D; Cutrell A; Harrigan R; Staszewski S; Katlama C; Pearce G; Tisdale M
    AIDS; 2000 Jan; 14(2):163-71. PubMed ID: 10708287
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of stavudine phenotype and thymidine analogues mutations on viral response to stavudine plus lamivudine in ALTIS 2 ANRS trial.
    Calvez V; Costagliola D; Descamps D; Yvon A; Collin G; Cécile A; Delaugerre C; Damond F; Marcelin AG; Matheron S; Simon A; Valantin MA; Katlama C; Brun-Vézinet F
    Antivir Ther; 2002 Sep; 7(3):211-8. PubMed ID: 12487389
    [TBL] [Abstract][Full Text] [Related]  

  • 16. R211K and L214F do not invariably confer high level phenotypic resistance to thymidine analogs in zidovudine-naive patients with M184V.
    Torti C; Gilleece Y; Hertogs K; Gazzard BG; Pozniak AL
    J Acquir Immune Defic Syndr; 2001 Apr; 26(5):514-5. PubMed ID: 11391177
    [No Abstract]   [Full Text] [Related]  

  • 17. Infection by zidovudine-resistant HIV-1 compromises the virological response to stavudine in a drug-naive patient.
    de Ronde A; van Dooren M; de Rooij E; van Gemen B; Lange J; Goudsmit J
    AIDS; 2000 Nov; 14(16):2632-3. PubMed ID: 11101087
    [No Abstract]   [Full Text] [Related]  

  • 18. Rate of thymidine analogue resistance mutation accumulation with zidovudine- or stavudine-based regimens.
    Kuritzkes DR; Bassett RL; Hazelwood JD; Barrett H; Rhodes RA; Young RK; Johnson VA;
    J Acquir Immune Defic Syndr; 2004 May; 36(1):600-3. PubMed ID: 15097303
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phenotypic and genotypic resistance patterns of HIV-1 isolates derived from individuals treated with didanosine and stavudine.
    Coakley EP; Gillis JM; Hammer SM
    AIDS; 2000 Jan; 14(2):F9-15. PubMed ID: 10708277
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Persistence of zidovudine-resistance mutations in HIV-1 isolates from patients removed from zidovudine therapy for at least 3 years and switched to a stavudine-containing regimen.
    Pellegrin I; Garrigue I; Caumont A; Pellegrin JL; Merel P; Schrive MH; Bonot P; Fleury H
    AIDS; 2001 May; 15(8):1071-3. PubMed ID: 11399996
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.